Please use this identifier to cite or link to this item:
https://hdl.handle.net/10316/107084
Title: | Sugar-Lowering Drugs for Type 2 Diabetes Mellitus and Metabolic Syndrome-Strategies for In Vivo Administration: Part-II | Authors: | Vieira, Raquel Souto, Selma B. Sánchez-López, Elena Machado, Ana López Severino, Patrícia Jose, Sajan Santini, Antonello Fortuna, Ana García, Maria Luisa Souto, Eliana B. |
Keywords: | diabetes mellitus; animal models; in vivo; administration routes | Issue Date: | 28-Aug-2019 | Publisher: | MDPI | Project: | M-ERA-NET/0004/2015-PAIRED Institute of Nanoscience and Nanotechnology under the project ART (2018) |
Serial title, monograph or event: | Journal of Clinical Medicine | Volume: | 8 | Issue: | 9 | Abstract: | Diabetes is a complex disease characterized by hyperglycemia, together with polyuria, polydipsia, and polyphagia. While Type 1 diabetes mellitus (T1DM) results from genetic, environmental, or immune dysfunction factors leading to pancreatic β-cell destruction depriving the organism from endogenous insulin, Type 2 diabetes mellitus (T2DM) is characterized by peripheral insulin resistance. Depending on the type of diabetes mellitus and drug mechanism to study, the animal model should be carefully selected among the wide variety of the currently available ones. This review discusses the most common animal models currently employed to study T1DM and T2DM. Moreover, an overview on the administration routes that could be used is also discussed. | URI: | https://hdl.handle.net/10316/107084 | ISSN: | 2077-0383 | DOI: | 10.3390/jcm8091332 | Rights: | openAccess |
Appears in Collections: | FFUC- Artigos em Revistas Internacionais |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
Sugarlowering-drugs-for-type-2-diabetes-mellitus-and-metabolic-syndromestrategies-for-in-vivo-administration-PartIIJournal-of-Clinical-Medicine.pdf | 581.4 kB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License